Reforgene listed among China's 2025 biopharma frontrunners

Recently, the 2025 China Biopharmaceutical Front-Runners 100 list was grandly released at the Shanghai Biomedical Investment and Financing Summit and Fudan Biomedical Innovation Development Forum. With its strong technological innovation capability, notable clinical progress of new drugs and excellent corporate growth, Reforgene was successfully selected into the "2025 China Biopharmaceutical Front-Runners 100 list", highlighting its benchmark position in the gene editing drug development field.

The solicitation and release of the Front-Runners list is an important measure to grasp forward-looking hotspots, explore scientific frontiers and build a "wind vane" for industry development. Since 2023, it has been held for three editions, selecting a group of benchmark enterprises across three fields: biomedicine, medical devices and digital health, attracting widespread social attention and discussion. Reforgene feels deeply that its selection into the 2025 China Biopharmaceutical Front-Runners 100 list is the industry's recognition of the company's technological breakthroughs in gene editing and its development path focused on clinical needs, and it further strengthens its original aspiration of "providing curative medicines for patients". In the future, it will continue to deepen its technology, improve drug accessibility, lead the industry with responsibility, help China's biomedicine advance toward a global source of innovation, and let innovative achievements benefit more patients.